# Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

> **NCT05029453** · PHASE4 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer
- Randomized Controlled Study

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT05029453
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-26
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029453, "Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05029453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*